Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study
Movement Disorders · 2024-06 · 39 (6) · 945-954
DOI: 10.1002/mds.29824 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 02.05.2024. Verfasst von C Warren Olanow und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Antiparkinson Agents, Carbidopa, Levodopa, Parkinson Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Double‐blind studies have demonstrated that motor complications in Parkinson's disease (PD) can be reduced with continuous delivery of levodopa. The DopaFuse system is a novel, intraoral micropump that attaches to a retainer and uses a propellant to deliver levodopa/carbidopa (LD/CD) continuously into the mouth.
Objectives
Evaluate the safety, pharmacokinetics, and efficacy of LD/CD delivered via the DopaFuse system compared to treatment with intermittent doses of standard oral LD/CD in PD patients with motor fluctuations.
Methods
This was a 2‐week, open‐label study (NCT04778176) in 16 PD patients treated with ≥4 levodopa doses/day and experiencing motor fluctuations. On Day 1 (clinic setting) patients received their usual dose of standard LD/CD; DopaFuse therapy was initiated on Day 2, and on Day 3 patients received DopaFuse plus a morning oral LD/CD dose. Patients returned home on Days 4–14 and returned for in‐clinic assessment on Day 15.
Results
Continuous DopaFuse delivery of LD/CD was associated with reduced variability in plasma levodopa levels compared to oral LD/CD (mean ± SD levodopa Fluctuation Index reduced from 2.15 ± 0.59 on Day1 to 1.50 ± 0.55 on Day 2 ( P = 0.0129) and to 1.03 ± 0.53 on Day 3 ( P < 0.0001)). This pharmacokinetic improvement translated into significantly reduced OFF time with DopaFuse therapy (reduction of −1.72 ± 0.37 h at Day 15; P = 0.0004) and increased ON time without severe dyskinesias (increase of 1.72 ± 0.37 h at Day 15; P = 0.0004) versus oral LD/CD administration. DopaFuse therapy was not associated with any clinically significant adverse events.
Conclusions
Continuous delivery of LD/CD using the DopaFuse system was associated with significantly less variability in plasma levodopa concentrations and reductions in OFF time compared to treatment with standard oral LD/CD therapy and was well tolerated. © 2024 International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA.
- Clintrex Research Corporation, Sarasota, Florida, USA.
- Luxembourg Institute of Health, Transversal Translational Medicine, Strassen, Luxembourg.
- Centro Integral de Neurociencias AC (CINAC), Hospital Universitario HM Puerta del Sur, Fundación de Investigación HM Hospitales, Madrid, Spain.
- Cooper Medical School of Rowan University, Camden, New Jersey, USA.
- Center for Health & Technology, University of Rochester, Rochester, New York, USA.
ORCID-Profile: C Warren Olanow, Michele Matarazzo, Fabrizio Stocchi
Zitieren
APA
Olanow, C. W., McIntyre, D., Matarazzo, M., Leinonen, M., McGarry, A., Kamp, C., Kennedy, J., Torti, M., Kruger, R., Obeso, J. A., Stocchi, F., Heller, E., & Kieburtz, K. (2024). Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study. Movement Disorders, 39(6), 945-954. https://doi.org/10.1002/mds.29824
Vancouver
Olanow CW, McIntyre D, Matarazzo M, Leinonen M, McGarry A, Kamp C, et al. Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study. Movement Disorders. 2024;39(6):945-954. doi:10.1002/mds.29824
BibTeX
@article{Olanow2024,
author = {Olanow, C Warren and McIntyre, Deborah and Matarazzo, Michele and Leinonen, Mika and McGarry, Andrew and Kamp, Cornelia and Kennedy, Julie and Torti, Margherita and Kruger, Rejko and Obeso, José A and Stocchi, Fabrizio and Heller, Ephraim and Kieburtz, Karl},
title = {Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study},
journal = {Movement Disorders},
year = {2024},
volume = {39},
number = {6},
pages = {945--954},
doi = {10.1002/mds.29824}
}
EUVIMED